论文部分内容阅读
目的 分析甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎患儿的疗效。方法 选取2020年9月至2021年8月收治的难治性支原体肺炎患儿50例，按照不同的用药方案进行分组，每组25例，观察组采用阿奇霉素+甲泼尼龙治疗，对照组采用阿奇霉素治疗，比较两组症状持续时间、炎性反应、疗效及用药安全性。结果 观察组咳嗽消失时间、肺部阳性体征消失时间、体温恢复正常时间、住院时间短于对照组（P＜0.05）；观察组炎性因子指标低于对照组（P＜0.05）；观察组治疗总有效率[92.00%（23/25）]高于对照组[68.00%（“,”Objective To analyze the efficacy of methylprednisolone and azithromycin in the clinical treatment of refractory mycoplasma pneumonia in children. Methods Fifty children with refractory mycoplasma pneumonia admitted from September 2020 to August 2021 were selected and divided into groups according to different medication regimens， 25 cases in each group， the observation group was treated with azithromycin + methylprednisolone， and the control group was treated with azithromycin. The duration of symptoms， inflammatory reaction， curative effect and drug safety were compared. Results The disappearance time of cough， the disappearance of positive lung signs， the disappearance of abnormal body temperature， and the discharge time of the observation group were shorter than those of the control group (P＜0.05); the inflammatory factor indexes of the observation group were lower than those of the control group (P＜0.05). The effective rate [92.00% (23/25)] is higher than that of the control group [68.00% (17/25)] (P＜0.05); the incidence of adverse reactions in the observation group and the control group are both 4.00% (1/25)， the difference is no statistical significance (P＞0.05). Conclusion Azithromycin combined with methylprednisolone has a significant clinical effect in the treatment of children with refractory mycoplasma pneumonia. After using this therapy， children can quickly alleviate the symptoms of pneumonia， efficiently inhibit the inflammatory reaction， significantly improve the curative effect， without significantly increasing the risk of medication.